

References

This is the reference list for the ACE Clinical Guidance "Initiating basal insulin in type 2 diabetes mellitus".

1. Epidemiology & Disease Control Division and Policy Research & Surveillance Group. National Population Health Survey 2020 (Household Interview and Health Examination). Singapore: Ministry of Health and Health Promotion Board; 2020.
2. Quah JHM, Liu YP, Luo N, et al. Younger adult type 2 diabetic patients have poorer glycaemic control: a cross-sectional study in a primary care setting in Singapore. *BMC Endocr Disord*. 2013;13:18.
3. Toh MPHS, Wu CX, Leong HSS. Association of younger age with poor glycemic and cholesterol control in Asians with type 2 diabetes mellitus in Singapore. *J Endocrinol Metab*. 2011;1(1):27-37.
4. Luo M, Lim WY, Tan CS, et al. Longitudinal trends in HbA1c and associations with comorbidity and all-cause mortality in Asian patients with type 2 diabetes: A cohort study. *Diabetes Res Clin Pract*. 2017;133:69-77.
5. American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes - 2024. *Diabetes Care*. 2024;47(Suppl 1):S158-78.
6. Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2020;11:Cd005613.
7. Swinnen S, Simon A, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2011(7):Cd006383.
8. Zhou W, Tao J, Zhou X, et al. Insulin degludec, a novel ultra-long-acting basal insulin versus insulin glargine for the management of type 2 diabetes: A systematic review and meta-analysis. *Diabetes Ther*. 2019;10(3):835-52.
9. Knudsen S, Lapolla A, Schultes B, et al. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT). *Diabet Med*. 2019;36(7):868-77.
10. Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients With type 2 diabetes: The SWITCH 2 randomized clinical trial. *J Am Med Assoc*. 2017;318(1):45-56.
11. Philis-Tsimikas A, Klonoff D, Khunti K, et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. *Diabetologia*. 2020;63(4):698-710.
12. Poh J, Tam KT. Registration of similar biological products – Singapore’s approach. *Biologics*. 2011;39(5):343-5.
13. Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. *Diabetes Care*. 2015;38(12):2226-33.
14. Wong S, Lee J, Ko Y, et al. Perceptions of insulin therapy amongst Asian patients with diabetes in Singapore. *Diabet Med*. 2011;28(2):206-11.
15. Chan WB, Chen JF, Goh S-Y, et al. Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience. *Diabetes Metab Syndr Obes*. 2017;10:521-32.

16. Ji L, Zhang P, Weng J, et al. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled by oral hypoglycemic agents in China—study design and baseline characteristics. *Diabetes Technol Ther*. 2015;17(10):735-44.
17. Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. *Diabetes Obes Metab*. 2018;20(3):488-96.
18. Berard L, Antonishyn N, Arcudi K, et al. Insulin Matters: A practical approach to basal insulin management in type 2 diabetes. *Diabetes Ther*. 2018;9(2):501-19.
19. Forst T, Choudhary P, Schneider D, et al. A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. *Diabetes Metab Res Rev*. 2021;37(6):e3418.
20. Muneer SM. Initiation of basal insulin in patients with uncontrolled type 2 diabetes mellitus. *ABC Res Alert*. 2019;7(3):155-8.
21. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. *Diabetes Care*. 2001;24(4):758-67.
22. Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. *Circ Res*. 2018;122(10):1439-59.
23. Scheen AJ. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. *Diabetes Metab J*. 2019;45(2):110-21.
24. Abdi H, Azizi F, Amouzegar A. Insulin monotherapy versus insulin combined with other glucose-lowering agents in type 2 diabetes: A narrative review. *Int J Endocrinol Metab*. 2018;16(2):e65600.
25. Yang Y, Chen S, Pan H. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes. *Medicine (Baltimore)*. 2017;96(21):e6944.
26. Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med*. 1999;130(5):389-96.
27. Zhu L, Ang L, Tan W, et al. A study to evaluate the prevalence of impaired awareness of hypoglycaemia in adults with type 2 diabetes in outpatient clinic in a tertiary care centre in Singapore. *Ther Adv Endocrinol Metab*. 2017;8(5):69-74.
28. Cryer PE. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. *N Engl J Med*. 2004;350:2272-9.
29. Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. *Lancet*. 1994;344:283-7.
30. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. *Diabetes*. 1993;42(11):1683-9.